Micron Technology and Sandisk got crushed last week after Alphabet Google detailed an algorithm called TurboQuant that the market feared would dent demand for memory chips. Mizuho analyst Vijay Rakesh reiterated Outperform ratings on both Micron and Sandisk in a research note, counseling traders to “buy the TurboQuant memory pullback.” Rakesh maintained a $710 price target for Sandisk and a $530 t...
Micron Technology and Sandisk got crushed last week after Alphabet Google detailed an algorithm called TurboQuant that the market feared would dent demand for memory chips. Mizuho analyst Vijay Rakesh reiterated Outperform ratings on both Micron and Sandisk in a research note, counseling traders to “buy the TurboQuant memory pullback.” Rakesh maintained a $710 price target for Sandisk and a $530 target for Micron.
A Radio-Canada reporter noticed his maple syrup tasted odd; testing revealed it was adulterated with cane syrup An investigation by Canada ’s national broadcaster has found that a major Quebec producer has been diluting its maple syrup with cane sugar and selling the fraudulent product to grocery chains. In a sting operation that involved false identities and covert recordings, journalists from Ra...
A Radio-Canada reporter noticed his maple syrup tasted odd; testing revealed it was adulterated with cane syrup An investigation by Canada ’s national broadcaster has found that a major Quebec producer has been diluting its maple syrup with cane sugar and selling the fraudulent product to grocery chains. In a sting operation that involved false identities and covert recordings, journalists from Radio-Canada’s Enquête programme found that a low-cost syrup sold in major grocery store chains was heavily diluted. Continue reading...
quantic69/iStock via Getty Images While the Trump administration has touted that having Medicare Part D cover weight loss medicines wouldn't pose too much of a financial burden because of drug prices negotiated with Novo Nordisk ( NVO ) and Eli Lilly ( LLY ), a new analysis is challenging that claim. Researchers from Vanderbilt University found that based on two models, covering Novo's Wegovy and ...
quantic69/iStock via Getty Images While the Trump administration has touted that having Medicare Part D cover weight loss medicines wouldn't pose too much of a financial burden because of drug prices negotiated with Novo Nordisk ( NVO ) and Eli Lilly ( LLY ), a new analysis is challenging that claim. Researchers from Vanderbilt University found that based on two models, covering Novo's Wegovy and Ozempic would come out to either ~$4.8B or ~$3.9B in annual spending. While the negotiated prices would lead to ~$933M in savings the first year, that amount only covers 4.4% of the estimated 12.4M Part D beneficiaries who could be eligible to receive the drugs under the administration's guidelines. The authors noted in their JAMA article that its findings could lead to pushback from Medicare insurers. "Plans may be unwilling to accept the trade-off of expanding obesity-indication coverage in exchange for lower per-fill prices under the BALANCE model, given the potential budget implications." More on Novo Nordisk Novo Nordisk: I Admit That I Was Really Wrong (Downgrade) Novo Nordisk: Why I Still Find It An Interesting Opportunity Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market Novo’s Wegovy expands reach in UK with latest NICE recommendation Novo’s China obesity drug posts positive mid-stage trial results
Nuclear power isn't new technology; we've had nuclear plants since the 1950s. But for various reasons both political and practical, it didn't catch on in much of the world. Only France derives a majority of its electricity (about 70%) from nuclear energy. But that has been changing for a couple of years now, and the closure of the Strait of Hormuz has likely changed the equation for many countries...
Nuclear power isn't new technology; we've had nuclear plants since the 1950s. But for various reasons both political and practical, it didn't catch on in much of the world. Only France derives a majority of its electricity (about 70%) from nuclear energy. But that has been changing for a couple of years now, and the closure of the Strait of Hormuz has likely changed the equation for many countries already working to expand their nuclear capacity and should accelerate the nuclear renaissance. That renaissance is global and will be playing out for years to come, and one companyis at the center of it all. Now is the time to consider adding it to your portfolio. Continue reading
Treasuries wiped out an early slump as investor focus turned to the risk that surging energy prices will become a drag on economic growth. Yields were lower by about a basis point at midday in New York after erasing increases of six to seven basis points. They had risen along with oil benchmarks after US President Donald Trump took a threatening tone toward Iran in a speech. Bloomberg's Ira Jersey...
Treasuries wiped out an early slump as investor focus turned to the risk that surging energy prices will become a drag on economic growth. Yields were lower by about a basis point at midday in New York after erasing increases of six to seven basis points. They had risen along with oil benchmarks after US President Donald Trump took a threatening tone toward Iran in a speech. Bloomberg's Ira Jersey and Robert Tipp, PGIM Fixed Income Managing Director, Chief Investment Strategist, and Head of Global Bonds join Carol Massar and Tim Stenovec to discuss what this sell off means for markets. (Source: Bloomberg)
RiverNorthPhotography/iStock Unreleased via Getty Images Shares of Cintas ( CTAS ) could offer an attractive entry point ahead of its proposed acquisition of UniFirst ( UNF ) , according to new analysis from UBS , which points to stronger-than-expected results at the target company. UniFirst ( UNF ) reported fiscal second-quarter revenue of $623 million, topping consensus estimates of $615 million...
RiverNorthPhotography/iStock Unreleased via Getty Images Shares of Cintas ( CTAS ) could offer an attractive entry point ahead of its proposed acquisition of UniFirst ( UNF ) , according to new analysis from UBS , which points to stronger-than-expected results at the target company. UniFirst ( UNF ) reported fiscal second-quarter revenue of $623 million, topping consensus estimates of $615 million, while adjusted earnings before interest, taxes, depreciation and amortization reached $70 million, ahead of expectations for $64 million. The results included a $2.5 million legal expense tied to an employee-related issue. UBS analyst Joshua Chan on Thursday said the performance supports the strategic case for Cintas’ planned acquisition, describing the deal as a meaningful opportunity to create value. Uniform segment shows resilience UniFirst’s ( UNF ) core uniform business delivered modestly stronger growth than expected, with organic revenue rising 2.8% year over year, slightly ahead of forecasts and an improvement from the prior quarter. The company cited stronger new customer wins compared with a year earlier. Margins in the segment also edged above expectations, even as they declined from last year due in part to the legal expense and ongoing investments in growth. Lower merchandise costs provided some support to profitability. Nuclear unit drives upside A rebound in UniFirst’s ( UNF ) more volatile nuclear services segment contributed to the earnings beat. Revenue declines were far less severe than anticipated, and margins came in well above forecasts, adding incremental upside to overall results. Meanwhile, the first aid division continued to post strong top-line growth, though profitability remained limited. Deal seen creating long-term value UBS maintains that the proposed acquisition would strengthen Cintas’ ( CTAS ) position in the uniform and facility services market, where it already serves more than one million businesses across North America. The firm reit...
Comcast Corporation (NASDAQ:CMCSA) earns a place on our list of the 8 Most Undervalued Value Stocks to Buy Right Now. Analysts’ sentiment on Comcast Corporation (NASDAQ:CMCSA) remains mixed as of March 30, 2026, despite the consensus price estimate of $32.50, implying a 13.50% increase. To enable real-time AI applications closer to end users across its […]
Comcast Corporation (NASDAQ:CMCSA) earns a place on our list of the 8 Most Undervalued Value Stocks to Buy Right Now. Analysts’ sentiment on Comcast Corporation (NASDAQ:CMCSA) remains mixed as of March 30, 2026, despite the consensus price estimate of $32.50, implying a 13.50% increase. To enable real-time AI applications closer to end users across its […]
Seeing the S&P 500 (SNPINDEX: ^GSPC) index down more than 4% year to date is painful. But it might provide some comfort knowing that a number of areas in the market are performing much better. The rotation that took place in U.S. equities earlier this year has made value, defensive, dividend, and small-cap stocks the new leaders. And several multiyear laggards have turned into stellar performers i...
Seeing the S&P 500 (SNPINDEX: ^GSPC) index down more than 4% year to date is painful. But it might provide some comfort knowing that a number of areas in the market are performing much better. The rotation that took place in U.S. equities earlier this year has made value, defensive, dividend, and small-cap stocks the new leaders. And several multiyear laggards have turned into stellar performers in 2026. This is most evident in the dividend stock category . Of more than 120 U.S. dividend equity exchange-traded funds (ETFs), nearly 90 of them have produced positive returns year to date. A dozen are up more than 8%. Nearly all of them are outperforming the S&P 500. Continue reading
US Defense Stocks Take Epic Fury Beating, Leaving UBS Asking Why Despite the launch of Operation Epic Fury against Iran in late February, U.S. defense stocks have moved lower rather than higher, prompting a UBS analyst to pen a note to clients this week attempting to answer why the makers of missiles and tanks failed to sustain a wartime rally. Analyst Allyson Gordon asked the question: "Why Is US...
US Defense Stocks Take Epic Fury Beating, Leaving UBS Asking Why Despite the launch of Operation Epic Fury against Iran in late February, U.S. defense stocks have moved lower rather than higher, prompting a UBS analyst to pen a note to clients this week attempting to answer why the makers of missiles and tanks failed to sustain a wartime rally. Analyst Allyson Gordon asked the question: "Why Is US Defense Performance Lackluster?" Let's start with iShares U.S. Aerospace & Defense ETF, or ITA, a basket of major U.S. defense firms. ITA caught an early bid in the first phase of Operation Epic Fury, but the rally failed to hold shortly after that. By late March, the fund was down nearly 16%. The fund has since rebounded in recent sessions, trading around $223 on Thursday morning, but the defense complex's inability to sustain a war-driven rally caught investors off guard. Gordon provided her take on why defense stocks has underperformed during the first month of the conflict: Defense is one of the more asked groups on "lack of outperformance" in the wake of the Middle East conflict – I think a lot is in part a function of a high starting point with a ton of money piling into Defense at the end of 2025/start of 2026 on geopolitical tension and budget optimism, along with these being non-AI/non-cyclical big cap stocks attached to a good theme (i.e. exposure diversification). Now, there are also questions on midterms and supplemental. I still sense investors holding on but poor performance is forcing some cautious sentiment creep. RTX is the one investors are fighting the hardest on the recent lag. She added: Trading Color: Clear de-risking. Initially saw a rush of demand to start the year, but now the desk is much better for sale especially from the Long Only community. Most skewed in RTX, Lockheed Martin, Lam Research and Parsons. In a separate note, Melius analyst Scott Mikus saw an opportunity in the sliding shares of RTX, formerly Raytheon Technologies Corporation. He ...
AMAT and LRCX surge as AI chip demand lifts semiconductor equipment makers, positioning them to mirror NVDA's long-term growth despite market volatility.
AMAT and LRCX surge as AI chip demand lifts semiconductor equipment makers, positioning them to mirror NVDA's long-term growth despite market volatility.